Delphia Therapeutics
delphiatx.com
Actively hiring
Medical AI
Precision Medicine
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Nextech Invest, Taiho Ventures
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Nextech Invest 
Taiho Ventures Similar startupsby what they do, their industry and backers
Cellply offers an automated platform for functional precision medicine.
Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS)…
Mindpeak transforms tissue into high-dimensional data, enabling the discovery of AI-driven biomarkers that guide targeted therapies and…
About UsGET TO KNOWOur Founders The medical potential of AI and metabolite Dr. Leila Pirhajico-founderOn Beyond Genome: Opportunities and…
Sano’s end-to-end precision medicine platform de-risks trials, enabling clinical operations teams to move 10x faster and reduce cost by 5x.
Founded in 2021 by four Seoul National University medical researchers, Portrai fuses spatial biology and AI to make drug development…
News
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer
CAMBRIDGE, MA, May 26, 2026 - Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology - activation lethality - which targets cancer's surprising vulnerability to oncogene overactivation, today
Read more
Report
Delphia Therapeutics Appoints David P. Kerstein, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., May 26, 2026--Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology - activation lethality - which targets cancer
Read more
Report
Report
Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors
CAMBRIDGE, MA, December 9, 2025 - Delphia Therapeutics, Inc. (Delphia), a biopharmaceutical company pioneering an innovative new area of cancer biology - activation lethality - which targets cancer's surprising vulnerability to oncogene overactivation, to
Read more
Report
AACR-NCI-EORTC 2025: Activation Lethality through the WNT/b-catenin pathway drives efficacy in colorectal cancer
The post AACR-NCI-EORTC 2025: Activation Lethality through the WNT/b-catenin pathway drives efficacy in colorectal cancer appeared first on Delphia Therapeutics.
Read more
Report
Pro access
Upgrade to see all 13 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.